%	O
%	O
TITLE	O

Human	O
papillomavirus	O
prevalence	B-Incidence_or_Prevalence
in	O
invasive	O
laryngeal	O
cancer	O
in	O
the	O
United	B-Study_Location
States	I-Study_Location
.	O

%	O
%	O
ABSTRACT	O

Human	O
papillomavirus	O
(	O
HPV	O
)	O
is	O
a	O
major	O
risk	O
factor	O
for	O
specific	O
cancers	O
of	O
the	O
head	O
and	O
neck	O
,	O
particularly	O
malignancies	O
of	O
the	O
tonsil	O
and	O
base	O
of	O
the	O
tongue	O
.	O

However	O
,	O
the	O
role	O
of	O
HPV	O
in	O
the	O
development	O
of	O
laryngeal	O
cancer	O
has	O
not	O
been	O
definitively	O
established	O
.	O

We	O
conducted	O
a	O
population	B-Study_Type
-	I-Study_Type
based	I-Study_Type
,	I-Study_Type
cancer	I-Study_Type
registry	I-Study_Type
study	I-Study_Type
to	O
evaluate	O
and	O
characterize	O
the	O
genotype	O
-	O
specific	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
in	O
invasive	O
laryngeal	O
cancer	O
cases	O
diagnosed	O
in	O
the	O
U	B-Study_Location
.	I-Study_Location
S	I-Study_Location
.	I-Study_Location
The	O
presence	O
of	O
genotype	O
-	O
specific	O
HPV	O
DNA	O
was	O
evaluated	O
using	O
the	O
Linear	O
Array	O
HPV	O
Genotyping	O
Test	O
and	O
the	O
INNO	O
-	O
LiPA	O
HPV	O
Genotyping	O
Assay	O
in	O
formalin	O
-	O
fixed	O
paraffin	O
embedded	O
tissue	B-HPV_Sample_Type
from	O
148	B-Study_Cohort
invasive	I-Study_Cohort
laryngeal	I-Study_Cohort
cancer	I-Study_Cohort
cases	I-Study_Cohort
diagnosed	O
in	O
1993	B-Study_Time
-	I-Study_Time
2004	I-Study_Time
within	O
the	O
catchment	O
area	O
of	O
three	O
U	B-Study_Location
.	I-Study_Location
S	I-Study_Location
.	I-Study_Location

SEER	O
cancer	O
registries	O
.	O
HPV	O
DNA	O
was	O
detected	O
in	O
31	O
of	O
148	O
(	O
21	O
%	O
)	O
invasive	O
laryngeal	O
cancers	O
.	O

Thirteen	O
different	O
genotypes	O
were	O
detected	O
.	O

Overall	O
,	O
HPV	O
16	O
and	O
HPV	O
33	O
were	O
the	O
most	O
commonly	O
detected	O
types	O
.	O

HPV	O
was	O
detected	O
in	O
33	O
%	O
(	O
9	O
/	O
27	O
)	O
of	O
women	O
compared	O
with	O
18	O
%	O
(	O
22	O
/	O
121	O
)	O
of	O
men	O
(	O
pâ€Š=â€Š0	O
.	O
08	O
)	O
.	O

After	O
adjustment	O
for	O
age	O
and	O
year	O
of	O
diagnosis	O
,	O
female	O
patients	O
were	O
more	O
likely	O
to	O
have	O
HPV	O
-	O
positive	O
laryngeal	O
tumors	O
compared	O
to	O
males	O
(	O
adjusted	O
OR	O
2	O
.	O
84	O
,	O
95	O
%	O
CI	O
1	O
.	O
07	O
-	O
7	O
.	O
51	O
)	O
.	O

Viral	O
genotype	O
differences	O
were	O
also	O
observed	O
between	O
the	O
sexes	O
.	O

While	O
HPV	O
16	O
and	O
18	O
constituted	O
half	O
of	O
HPV	O
-	O
positive	O
cases	O
occurring	O
in	O
men	O
,	O
among	O
women	O
,	O
only	O
1	O
was	O
HPV	O
16	O
positive	O
and	O
none	O
were	O
positive	O
for	O
HPV	O
18	O
.	O

Overall	O
5	O
-	O
year	O
survival	O
did	O
not	O
vary	O
by	O
HPV	O
status	O
.	O
HPV	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
a	O
subset	O
of	O
laryngeal	O
cancers	O
and	O
its	O
role	O
may	O
be	O
more	O
predominant	O
in	O
women	O
compared	O
to	O
men	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

This	O
evaluation	O
was	O
part	O
of	O
an	O
initiative	O
by	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
to	O
examine	O
the	O
distribution	O
of	O
HPV	O
genotypes	O
in	O
anogenital	O
and	O
head	O
and	O
neck	O
cancers	O
diagnosed	O
in	O
the	O
U	B-Study_Location
.	I-Study_Location
S	I-Study_Location
.	O
prior	O
to	O
the	O
implementation	O
of	O
the	O
prophylactic	O
HPV	O
vaccine	O
This	O
study	O
was	O
approved	O
by	O
the	O
CDC	O
Institutional	O
Review	O
Board	O
(	O
IRB	O
)	O
,	O
the	O
IRB	O
of	O
the	O
University	O
of	O
Hawaii	O
Human	O
Studies	O
Program	O
,	O
the	O
IRB	O
of	O
the	O
University	O
of	O
Iowa	O
,	O
and	O
the	O
IRB	O
of	O
the	O
University	O
of	O
Southern	O
California	O
.	O

Individual	O
informed	O
consent	O
was	O
not	O
obtained	O
as	O
study	O
specimens	B-HPV_Sample_Type
were	O
deemed	O
to	O
be	O
exempt	O
from	O
consent	O
related	O
Health	O
Insurance	O
Portability	O
and	O
Accountability	O
requirements	O
by	O
the	O
NIH	O
Office	O
of	O
Human	O
Subjects	O
Research	O
Protections	O
and	O
the	O
individual	O
site	O
IRBs	O
since	O
the	O
de	O
-	O
identified	O
,	O
archival	O
specimens	B-HPV_Sample_Type
were	O
retrospectively	O
collected	O
as	O
part	O
of	O
the	O
National	O
Cancer	O
Institute’s	O
Surveillance	O
,	O
Epidemiology	O
,	O
and	O
End	O
-	O
Results	O
Residual	O
Tissue	O
Repository	O
program	O
.	O

All	O
patient	O
data	O
were	O
de	O
-	O
identified	O
and	O
anonymized	O
prior	O
to	O
analysis	O
.	O

Invasive	O
laryngeal	O
cancer	O
was	O
defined	O
based	O
on	O
the	O
International	O
Classification	O
of	O
Diseases	O
for	O
Oncology	O
Version	O
3	O
Laryngeal	O
cancer	O
cases	O
were	O
selected	O
from	O
patients	O
with	O
histologically	O
-	O
confirmed	O
malignancies	O
of	O
any	O
histological	O
subtype	O
;	O
squamous	O
cell	O
carcinomas	O
comprised	O
the	O
majority	O
.	O

All	O
subsites	O
of	O
the	O
larynx	O
were	O
evaluated	O
including	O
the	O
supraglottis	O
(	O
C321	O
)	O
,	O
glottis	O
(	O
C320	O
)	O
,	O
subglottis	O
(	O
C322	O
)	O
,	O
and	O
overlapping	O
and	O
unspecified	O
lesions	O
(	O
C328	O
and	O
C329	O
)	O
.	O

Cases	O
were	O
diagnosed	O
in	O
1993–2004	O
within	O
the	O
catchment	O
area	O
of	O
three	O
population	O
-	O
based	O
cancer	O
registries	O
.	O

The	O
Hawaii	O
Tumor	O
Registry	O
,	O
the	O
Iowa	O
Cancer	O
Registry	O
,	O
and	O
Los	O
Angeles	O
County	O
Cancer	O
Surveillance	O
Program	O
are	O
part	O
of	O
the	O
National	O
Cancer	O
Institute’s	O
(	O
NCI	O
)	O
Surveillance	O
,	O
Epidemiology	O
,	O
and	O
End	O
-	O
Results	O
(	O
SEER	O
)	O
program	O
and	O
operate	O
affiliated	O
Residual	O
Tissue	O
Repositories	O
(	O
RTR	O
)	O
The	O
RTRs	O
consist	O
of	O
a	O
collection	O
of	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
malignant	O
tumor	O
(	O
herein	O
referred	O
to	O
only	O
as	O
‘‘tumor’’	O
)	O
tissue	B-HPV_Sample_Type
specimens	I-HPV_Sample_Type
from	O
cancer	O
patients	O
diagnosed	O
within	O
the	O
catchment	O
area	O
of	O
the	O
three	O
registries	O
.	O

Through	O
linkage	O
with	O
registry	O
data	O
,	O
tissue	B-HPV_Sample_Type
specimens	I-HPV_Sample_Type
were	O
annotated	O
with	O
de	O
-	O
identified	O
,	O
high	O
-	O
quality	O
demographic	O
,	O
clinical	O
,	O
treatment	O
,	O
and	O
pathologic	O
data	O
.	O

Stage	O
was	O
based	O
on	O
the	O
SEER	O
staging	O
classification	O
system	O
defining	O
the	O
extent	O
of	O
disease	O
involvement	O
as	O
localized	O
,	O
regional	O
spread	O
,	O
and	O
distant	O
metastases	O
Vital	O
status	O
and	O
length	O
of	O
survival	O
were	O
available	O
for	O
a	O
subset	O
of	O
cases	O
.	O

FFPE	O
tissue	B-HPV_Sample_Type
specimens	I-HPV_Sample_Type
were	O
prepared	O
at	O
each	O
site	O
following	O
a	O
uniform	O
protocol	O

to	O
avoid	O
cross	O
-	O
contamination	O
.	O

A	O
representative	O
block	O
from	O
each	O
cancer	O
case	O
was	O
selected	O
and	O
sectioned	O
using	O
a	O
new	O
disposable	O
blade	O
for	O
each	O
case	O
.	O

The	O
first	O
and	O
last	O
sections	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
)	O
and	O
intervening	O
sections	O
(	O
10	O
microns	O
)	O
were	O
transferred	O
into	O
2	O
ml	O
conical	O
tubes	O
(	O
Simport	O
,	O
Beloeil	O
,	O
Canada	O
)	O
.	O

H	O
&	O
E	O
sections	O
were	O
reviewed	O
by	O
a	O
study	O
pathologist	O
(	O
E	O
.	O
R	O
.	O
U	O
.	O
)	O
at	O
the	O
CDC	O
to	O
confirm	O
the	O
presence	O
of	O
malignancy	O
.	O

HPV	O
genotyping	O
was	O
conducted	O
at	O
the	O
CDC	O
laboratories	O
.	O

One	O
suitable	O
tissue	B-HPV_Sample_Type
sample	I-HPV_Sample_Type
from	O
each	O
case	O
was	O
processed	O
using	O
high	O
temperature	O
assisted	O
tissue	B-HPV_Sample_Type
lysis	O

and	O
automated	O
DNA	O
purification	O
with	O
a	O
Chemagic	O
MSM1	O
(	O
PerkinElmer	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
.	O

The	O
resulting	O
100	O
mL	O
DNA	O
eluate	O
was	O
tested	O
immediately	O
or	O
stored	O
at	O
220C	O
until	O
testing	O
.	O

A	O
blank	O
sample	O
without	O
tissue	B-HPV_Sample_Type
was	O
included	O
in	O
every	O
sample	O
batch	O
to	O
monitor	O
potential	O
cross	O
contamination	O
.	O

HPV	O
testing	O
was	O
performed	O
as	O
previously	O
described	O
Briefly	O
,	O
all	O
samples	O
were	O
tested	O
using	O
the	O
Linear	O
Array	O
HPV	O
Genotyping	O
Test	O
(	O
LA	O
,	O
Roche	O
Diagnostics	O
,	O
Indianapolis	O
,	O
IN	O
)	O
,	O
a	O
PCR	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
based	I-HPV_Lab_Technique
assay	I-HPV_Lab_Technique
targeting	O
a	O
450	O
-	O
bp	O
consensus	O
region	O
of	O
the	O
L1	O
HPV	O
genome	O
and	O
detecting	O
37	O
HPV	O
genotypes	O
(	O
6	O
,	O
11	O
,	O
16	O
,	O
18	O
,	O
26	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O

40	O
,	O
42	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
53	O
,	O
54	O
,	O
55	O
,	O
56	O
,	O
58	O
,	O
59	O
,	O
61	O
,	O
62	O
,	O
64	O
,	O
66	O
,	O
67	O
,	O
68	O
,	O
69	O
,	O
70	O
,	O
71	O
,	O
72	O
,	O
73	O
,	O
81	O
,	O

82	O
,	O
83	O
,	O
84	O
,	O
89	O
,	O
IS39	O
)	O
.	O

Amplification	O
of	O
the	O
human	O
b	O
-	O
globin	O
gene	O
was	O
included	O
as	O
an	O
internal	O
control	O
.	O

Samples	O
testing	O
negative	O
for	O
b	O
-	O
globin	O
and	O
HPV	O
in	O
the	O
Roche	O
assay	O
were	O
subsequently	O
tested	O
using	O
the	O
INNO	O
-	O
LiPA	O
HPV	O
Genotyping	O
Assay	O
(	O
LiPA	O
,	O
Innogenetics	O
,	O
Gent	O
,	O
Belgium	O
)	O
,	O
a	O
PCR	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
based	I-HPV_Lab_Technique
assay	I-HPV_Lab_Technique
with	O
an	O
internal	O
control	O
and	O
primers	O
targeting	O
a	O
65	O
bp	O
region	O
of	O
the	O
HPV	O
L1	O
gene	O
.	O

LiPA	O
detects	O
26	O
of	O
the	O
same	O
types	O
covered	O
in	O
the	O
Roche	O
assay	O
in	O
addition	O
to	O
3	O
additional	O
types	O
(	O
HPV	O
43	O
,	O
44	O
,	O
74	O
)	O
.	O

This	O
second	O
assay	O
was	O
included	O
in	O
order	O
to	O
account	O
for	O
the	O
fixation	O
-	O
related	O
degradation	O
of	O
DNA	O
extracted	O
from	O
FFPE	O
tissue	B-HPV_Sample_Type
.	O

Specimens	B-HPV_Sample_Type
testing	O

negative	O
for	O
HPV	O
and	O
the	O
internal	O
control	O
in	O
both	O
two	O
assays	O
were	O
considered	O
inadequate	O
for	O
evaluation	O
.	O

Statistical	O
analyses	O
were	O
conducted	O
using	O
SAS	O
version	O
9	O
.	O
2	O
.	O

Overall	O
HPV	O
prevalence	B-Incidence_or_Prevalence
was	O
based	O
on	O
the	O
detection	O
of	O
one	O
or	O
more	O
HPV	O
genotypes	O
in	O
tumor	O
tissue	B-HPV_Sample_Type
.	O

Multiple	O
genotypes	O
detected	O
in	O
a	O
case	O
were	O
not	O
counted	O
more	O
than	O
once	O
in	O
overall	O
prevalence	B-Incidence_or_Prevalence
estimates	O
.	O

HPV	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O
59	O
,	O
66	O
,	O
and	O
68	O
were	O
considered	O
carcinogenic	O
,	O
or	O
high	O
-	O
risk	O
genotypes	O
All	O
other	O
genotypes	O
were	O
considered	O
to	O
be	O
non	O
-	O
carcinogenic	O
,	O
or	O
of	O
low	O
or	O
undetermined	O
risk	O
.	O

Comparisons	O
between	O
HPV	O
-	O
positive	O
and	O
HPV	O
-	O
negative	O
tumors	O
were	O
made	O
using	O
the	O
Chi	O
-	O
squared	O
statistic	O
for	O
discrete	O
variables	O
.	O

Unconditional	O
logistic	O
regression	O
was	O
used	O
to	O
estimate	O
odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
.	O

Variables	O
with	O
significance	O
level	O
,	O
0	O
.	O
10	O
in	O
univariate	O
analysis	O
were	O
included	O
in	O
multivariate	O
models	O
;	O
backward	O
elimination	O
was	O
used	O
to	O
select	O
the	O
final	O
model	O
.	O

Survival	O
analyses	O
excluded	O
22	O
cases	O
for	O
which	O
vital	O
status	O
and	O
length	O
of	O
survival	O
were	O
not	O
available	O
.	O

Survival	O
was	O
based	O
on	O
the	O
time	O
period	O
from	O
date	O
of	O
cancer	O
diagnosis	O
to	O
date	O
of	O
death	O
or	O
date	O
of	O
last	O
follow	O
-	O
up	O
.	O

Overall	O
five	O
-	O
year	O
survival	O
by	O
HPV	O
status	O
was	O
evaluated	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
and	O
the	O
Log	O
rank	O
-	O
test	O
.	O

Cox	O
proportional	O
hazards	O
regression	O
was	O
used	O
to	O
examine	O
the	O
relationship	O
of	O
HPV	O
status	O
and	O
covariates	O
with	O
overall	O
5	O
-	O
year	O
survival	O
.	O

Age	O
,	O
which	O
was	O
imputed	O
to	O
the	O
mid	O
-	O
point	O
of	O
5	O
-	O
year	O
age	O
groups	O
for	O
48	O
of	O
the	O
148	O
cases	O
for	O
which	O
single	O
age	O
was	O
not	O
available	O
,	O
was	O
included	O
as	O
a	O
continuous	O
covariate	O
in	O
all	O
models	O
.	O

All	O
tests	O
were	O
two	O
-	O
sided	O
and	O
a	O
P	O
value	O
,	O
0	O
.	O
05	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O

